The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review

Aaron S. Mansfield, MD,a Rebecca J. Brown, PhD,b,* Cormac Sammon, PhD,b Melinda J. Daumont, PhD,c Mike McKenna, MSc,d Jenine K. Sanzari, PhD,e Patrick M. Forde, MDf

aDivision of Medical Oncology, Mayo Clinic, Rochester, Minnesota
bPHMR Ltd., Berkeley Works, London, United Kingdom
cBristol-Myers Squibb, Braine-l’Alleud, Belgium
dHealth Outcomes Solutions Ltd., London, United Kingdom
eBristol-Myers Squibb, Lawrenceville, New Jersey
fBloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland

Received 8 February 2022; revised 15 March 2022; accepted 17 March 2022
Available online - 22 March 2022

ABSTRACT

Introduction: Given the emergence of combination of programmed cell death protein-1 and CTLA4 pathway blockade as effective treatment options in malignant pleural mesothelioma (MPM), there is interest in the extent to which programmed death-ligand 1 (PD-L1) expression may be prognostic of clinical outcomes and predictive of response to anti–programmed death (ligand) 1 (PD-[L]1) therapies.

Methods: MEDLINE and EMBASE electronic databases were searched until November 4, 2020. English-language randomized trials and observational studies that reported clinical outcomes and PD-L1 expression in adult patients (>18 or >20 y) with MPM were included. Forest plots were used to descriptively summarize clinical outcome data across studies.

Results: A total of 29 publications were identified providing data on the research question. Among the studies in which anti–PD-(L)1 therapies were not specified to have been used, 63% (10 of 16) found patients with tumors expressing PD-L1 (typically >1%) to have poorer survival than those with tumors expressing lower levels of PD-L1. Among the studies in which anti–PD-(L)1 therapies were used, 83% (five of six) did not reveal an association between survival and PD-L1 tumor expression. The single study directly comparing outcomes between those treated and untreated with anti–PD-(L)1 therapies across different PD-L1 cutoffs did not identify any differences between the groups.

Conclusions: The quality and consistency of the existing evidence base are currently insufficient to draw conclusions regarding a prognostic or predictive role of PD-L1 in MPM. Furthermore, high-quality studies on this topic are required to support the use of PD-L1 as a biomarker in MPM.
© 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.

*COrresponding author.

Disclosure: Dr. Mansfield reports receiving research support from Novartis and Verily; having remuneration to his institution for participation on advisory boards for AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, and Janssen; receiving travel support and payment from Shanghai Roche Pharmaceuticals Ltd; and being a nonremunerated director of the Mesothelioma Applied Research Foundation. Drs. Brown and Sammon are full-time employees at PHMR. PHMR received financial support from Bristol-Myers Squibb for the work, including the development of the literature review and preparation of the manuscript. Dr. Daumont is a full-time employee of Bristol-Myers Squibb and owns stock in Bristol-Myers Squibb. Mr. McKenna’s company provides consultancy services to Bristol-Myers Squibb. Dr. Sanzari is an employee of Bristol-Myers Squibb. Dr. Forde reports receiving research funding to his institution from AstraZeneca, Bristol-Myers Squibb, Daiichi, G1 Therapeutics, Genentech, Iteos, Janssen, Novartis, Sanofi, and Surface; serving as a DSMB member for Polaris and Flame; and being a nonremunerated director of the Mesothelioma Applied Research Foundation.

Address for correspondence: Rebecca J. Brown, PhD, PHMR Ltd., Berkeley Works, Berkley Grove, London NW1 8XY, United Kingdom. E-mail: rebecca.brown@phmr.com

Cite this article as: Mansfield AS, Brown RJ, Sammon C, et al. The predictive and prognostic nature of programmed death-ligand 1 in malignant pleural mesothelioma: a systematic literature review. JTO Clin Res Rep. 2022;3:100315.

© 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

ISSN: 2666-3643
https://doi.org/10.1016/j.jtocrr.2022.100315
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords: Mesothelioma; PD-L1; Prognostic; Predictive; Biomarker

Introduction

Malignant mesothelioma is an aggressive malignancy arising from mesothelial cells. It is a relatively rare form of cancer, most often observed in developed countries, with an average incidence rate of 20 per 1,000,000 per year in Europe, 9.9 per 1,000,000 in the United States of America (Surveillance, Epidemiology, and End Results database 1975–2016), 7 per 1,000,000 in Japan, and 40 per 1,000,000 in Australia. Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma, accounting for approximately 80% of cases and is linked to industrial pollutant and mineral fiber exposure, with approximately 80% of cases linked to asbestos exposure. Although asbestos has been banned in many developed countries for many years, the latency of MPM from exposure to clinical onset is approximately 40 years, and consequently the disease incidence has not yet declined.

In most patients, by the time MPM has been diagnosed, the disease is advanced and there are no surgical options. The prognosis is poor, with a 5-year survival rate of less than 5% in males and 10% in females. For many years, the standard of care for systemic treatment of advanced MPM has been combination chemotherapy with cisplatin and pemetrexed, an approach associated with an improvement in median overall survival (OS) of less than 3 months than cisplatin alone. The approval of nivolumab and ipilimumab combination therapy as a first-line treatment option in adults with unresectable MPM by the U.S. Food and Drug Administration on October 2, 2020, therefore represents a key development in the treatment of MPM, with trial results reporting a statistically significant and clinically meaningful improvement in OS relative to chemotherapy.

There is an urgent and unmet need for noninvasive biomarkers that can better predict patient response to treatments; however, as yet, no predictive biomarkers have been recommended or validated for clinical practice in MPM. Given the mechanism of action of nivolumab and other checkpoint inhibitors currently under investigation in MPM, the fact that up to 70% of MPM patient specimens tested have been found to be programmed death-ligand 1 (PD-L1) positive and the role of PD-L1 as a predictive biomarker in other tumor types, there is interest in the role PD-L1 expression assessed by immunohistochemistry (IHC) may play in the relationship between treatment and clinical outcomes in MPM.

This article reports the findings of a systematic literature review (SLR) that sought to collate the published literature regarding the relationship between PD-L1 expression, immunotherapy treatment, and clinical outcomes in MPM and to assess the extent to which it can be used to support a role of PD-L1 as a predictive biomarker in MPM.

Materials and Methods

Literature Search

An SLR was designed and refined to identify studies relevant to the review objectives. This SLR was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. An electronic search was performed in EMBASE (OvidSP) and MEDLINE databases using two sets of terms that broadly related to the health condition (MPM) and biomarker (PD-L1) under investigation. Searches were limited to English language, and publication type was limited to interventional studies (including single-arm and randomized trials) and observational studies in humans. No limit was placed on country or time frame. The search strategy was validated by cross-referencing search strategies with previous published SLRs and unpublished focused reviews and by ensuring known studies were identified. A complete copy of the search strategy used for each electronic database is reported in Supplementary Data 1.

Study Selection and Quality Assessment

After deduplication of the retrieved records, two analysts independently reviewed the results of the literature search. Studies were included or excluded according to the prespecified inclusion and exclusion criteria. Inclusion criteria included adult patients, diagnosed with having MPM of any stage, any line of therapy, randomized trials and observational studies, and clinical outcomes, including OS, progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Pediatric patients (<18 y), nonhuman studies, conference abstracts, case reports, editorials, letters, reviews, and non–English-language studies were excluded. Titles and abstracts were reviewed for all the retrieved records, and full-text articles were obtained for the included records for evaluation in a full-text review against the eligibility criteria. Any disagreements between analysts were resolved through discussion until a consensus was reached. Retrieved studies were critically appraised by a single reviewer for methodological quality using the Cochrane Risk of Bias tool (RoB2) for randomized controlled trials and the Risk of Bias In Non-Randomized Studies of Intervention (ROBINS) tool for
nonrandomized studies (results reported in Supplementary Data 2). Informed consent was not required for this study, given it included secondary analysis of existing data with no reported patient identifiers or risks to patients.

**Data Extraction and Synthesis**

Data from the included studies were extracted by one analyst and internally quality assured by a second independent analyst. Extracted data included study details and methodology; population characteristics (including disease characteristics and PD-L1 expression status); and PD-L1 diagnostic measurement methodology. Key clinical outcomes extracted were OS, PFS, ORR, and DCR. The association between PD-L1 expression status and disease prognosis was investigated. PD-L1 status was dichotomized according to cutoff thresholds reported in the primary studies, and crude and adjusted hazard ratios (aHRs) for key outcomes (OS and PFS) were calculated where data allowed. These results were reported descriptively and presented as forest plots. Where data on outcomes were missing, this was reported as “not reported.” Where reported, confidence intervals (CIs) and p values associated with statistical tests for differences in outcomes across PD-L1 groups were extracted. Although these data are used to provide statements regarding the extent to which results of individual studies are “statistically significant,” this is to provide the reader with some idea of the relative precision and magnitudes of the estimated associations and does not consider the impact of other factors that might be considered to influence statistical significance (statistical power, bias, etc.).

**Results**

**Literature Search**

A total of 767 records were identified through electronic database search (full search strategy can be found in Supplementary Data 1). The flow of studies through identification and study selection can be found in Figure 1. After exclusion of 132 duplicate publications, 635 publications were reviewed by title and abstract. Subsequently, 580 publications were excluded, and full-text articles were obtained and screened for 55 publications. A total of 26 publications were excluded for the following reasons: inclusion of peritoneal mesothelioma \((n=9)\), inappropriate study design \((n=8)\), outcomes not reported by PD-L1 expression \((n=4)\), population untested for PD-L1 expression using IHC \((n=4)\), and no outcomes of interest reported \((n=1)\). Finally, 29 publications were included in this SLR.

![Figure 1. Flowchart of the selection process for studies included in the systematic literature review on the prognostic and predictive effects of PD-L1 in MPM. MPM, malignant pleural mesothelioma; PD-L1, programmed death-ligand 1.](image)
| Study                          | Country                        | Enrolment Period | Sample Size | Treatment Received (Dose and Frequency) | Line of Therapy | Age, y Median (Range) | Clinical Outcomes Reported | Study Quality |
|-------------------------------|--------------------------------|------------------|-------------|-----------------------------------------|----------------|----------------------|----------------------------|---------------|
| Cantini et al., 2020          | The Netherlands                | NR               | 107         | Nivolumab (3 mg/kg IV, Q2w)             | Second          | 87.0                 | 69.0 (34-84)               | OS, PFS, ORR, DCR | Low           |
| Cedres et al., 2015           | Spain                          | 2000-2014        | 119         | NR                                      | NR             | 71.4                 | 69.0 (42-90)               | OS            | Moderate       |
| Chapel et al., 2019           | USA                            | NR               | 125         | NR                                      | NR             | 50.0                 | 69.0 (NR)                  | OS            | Low            |
| Combaz-Lair et al., 2016      | France                         | 1993-2014        | 58          | NR                                      | NR             | 77.6                 | 69.0 (58-83)               | OS            | Low            |
| De Perrot et al., 2020        | Canada                         | 2008-2016        | 85          | Chemotherapy (NR) + radiation treatment | First           | 83.0                 | 65.0 (41-82)               | OS            | High           |
| Ferdinandus et al., 2020      | NR                             | 2015-2019        | 27          | Pembrolizumab (10 mg/kg IV, Q2w)        | ≥ Second        | 85.2                 | 68.0 (51-82)               | OS, PFS, ORR | Moderate       |
| Forest et al., 2018           | France                         | 2002-2017        | 104         | NR                                      | NR             | 79.0                 | 73.0 (43-92)               | OS            | Low            |
| Inaguma et al., 2020          | NR                             | NR               | 172         | NR                                      | NR             | 84.3                 | 59.2 (NR)                  | OS            | Moderate       |
| Inaguma et al., 2020          | USA                            | NR               | 175         | NR                                      | NR             | 69.0                 | 59.2 (NR)                  | OS            | Low            |
| Jiang et al., 2020            | USA                            | 2016-2018        | 10          | Pembrolizumab (200 mg IV, Q3w) or Nivolumab (NR) | ≥ Second        | 66.7                 | 62.3 (NR)                  | OS, PFS       | High           |
| Kao et al., 2017              | Australia                      | 1992-2007        | 72          | NR                                      | NR             | 81.0                 | NR                        | OS            | Moderate       |
| Mansfield et al., 2014        | USA                            | 1987-2003        | 106         | NR                                      | NR             | 84.9                 | NR                        | OS            | Moderate       |
| Metaxas et al., 2018          | Switzerland, Australia         | 2015-2017        | 93          | Pembrolizumab (200 mg Q14-21d, 2 mg/kg Q21d, 10 mg/kg Q14d) | First           | 91.0                 | 68.0 (25-94)               | OS, PFS, ORR, DCR | Low           |
| Muller et al., 2020           | NR                             | 1989-2010        | 319         | NR                                      | First           | 74.3                 | 64.0 (29-85)               | OS            | Moderate       |
| Nguyen et al., 2018           | Australia                      | 2006-2016        | 58          | NR                                      | NR             | 84.0                 | 73.0 (NR)                  | OS            | Moderate       |
| Sobhani et al., 2019          | Italy                          | 2005-2016        | 62          | NR                                      | NR             | 82.0                 | 77.5 (37-92)               | OS            | Moderate       |
| Tallón de Lara, et al., 2018  | Switzerland                    | 1999-2009        | 145         | Cisplatin + pemetrexed (Q3w) or gemcitabine (Q3w) | NR             | 92.0                 | NR                        | OS            | Moderate       |
| Study                          | Country          | Enrolment Period | Sample Size | Treatment Received (Dose and Frequency) | Line of Therapy | % Male | Age, y Median (Range) | Clinical Outcomes Reported | Study Quality |
|-------------------------------|------------------|------------------|-------------|------------------------------------------|----------------|--------|----------------------|--------------------------------|---------------|
| Thapa et al., 2017            | Australia        | 1988-2014        | 329         | NR                                       | NR             | 83.2   | NR                   | OS                             | Moderate      |
| Watanabe et al., 2018         | Japan            | 1992-2016        | 32          | NR                                       | NR             | NR      | 60.5 (34-79)         | OS                             | Low           |
| Prospective observational studies |                |                  |             |                                          |                |        |                      |                                |               |
| Brosseau et al., 2019         | France           | 2008-2014        | 214         | Pemetrexed (NR) or platinum chemotherapy (NR) with or without bevacizumab (NR) | NR             | 83.7   | 66.9 (35-76)         | OS, PFS                        | Moderate      |
| Cedres et al., 2016           | Spain            | 2000-2014        | 27          | NR                                       | NR             | 70.4   | 68.0 (53-83)         | OS                             | Low           |
| Disselhorst et al., 2019      | NR               | 2016-2017        | 35          | Nivolumab (240 mg IV Q2w) + ipilimumab (1 mg/kg IV Q6w up to 4 doses) | ≥ Second       | 86.0   | 65.0 (37-79)         | OS, PFS, ORR, DCR              | Low           |
| Quispel-Janssen et al., 2018  | The Netherlands  | 2015-2016        | 34          | Nivolumab (3 mg/kg IV biweekly)          | ≥ Second       | 82.0   | 67.0 (50-81)         | OS, PFS, ORR, DCR              | Low           |
| Cross-sectional studies       |                  |                  |             |                                          |                |        |                      |                                |               |
| Salaroglio et al., 2019       | Italy            | 2016-2018        | 62          | NR                                       | NR             | 73.5   | 49.0 (52-85)         | OS, PFS                        | Low           |
| Nonrandomized trials          |                  |                  |             |                                          |                |        |                      |                                |               |
| Alley et al., 2017            | 6 countries (NR)| 2014-2014        | 25          | Pembrotilzumab (10 mg/kg IV, Q2w)        | ≥ Second       | 75.0   | 65.0 (57-73)         | OS, PFS, ORR                   | Moderate      |
| Chiarucci et al., 2020        | NR               | NR               | 40          | Tremelimumab + durvalumab                | NR             | NR     | 66.0 (42-83)         | OS                             | Moderate      |
| Okada et al., 2019            | Japan            | 2016-2018        | 34          | Nivolumab (240 mg IV, Q2w)               | ≥ Third         | 79.0   | 68.0 (43-78)         | OS, PFS, ORR, DCR              | Low           |
| Randomized trials             |                  |                  |             |                                          |                |        |                      |                                |               |
| Popat et al., 2020            | UK, Switzerland, Spain | 2017-2018        | 144         | Gemcitabine (1000 mg/m² IV, Q3w) or vinorelbine (30 mg/m², 60 mg/m², or 80 mg/m² IV, Q3w) vs. pembrolizumab (200 mg IV, Q3w) | ≥ Second       | 88.9   | 70.0 (52-83)         | OS, PFS, ORR                   | Some concern |
| Scherpereel et al., 2019      | France           | 2016             | 125         | Nivolumab (3 mg/kg IV Q2w) with or without ipilimumab (1 mg/kg IV, Q6w) | ≥ Second       | 84.0   | NR                   | OS, PFS, ORR, DCR              | Some concern |

aMean value reported.

bIQR reported.

DCR, disease control rate; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; USA, United States of America.
| Study                        | Detection Method | Primary Antibody | Cutoff Value, % |
|-----------------------------|------------------|------------------|----------------|
| Retrospective studies       |                  |                  |                |
| Cantini et al., 2020        | IHC              | NR               | NR             |
|                            |                  | 22C3 or SP263    | NR             |
|                            |                  | E1L3N            | 1:1200         |
|                            |                  | Cell Signaling Technology, Danvers, MA | >1 |
| Cedrés et al., 2015         | IHC              | Rabbit           | MAB            |
|                            |                  | E1L3N            | 1:100          |
|                            |                  | Cell Signaling Technology, Danvers, MA | >1 |
| Combaz-Lair et al., 2016    | IHC              | Rabbit           | MAB            |
|                            |                  | E1L3N            | 1:100          |
|                            |                  | Spring Bioscience | >1 |
| Chapel et al., 2019         | IHC              | NR               | NR             |
|                            |                  | 22C3             | NR             |
|                            |                  | 28-8             | 1:200          |
|                            |                  | Abcam Inc., Toronto, Ontario, Canada | >1 |
| De Perrot et al., 2020      | IHC              | NR               | NR             |
|                            |                  | 28-8             | 1:200          |
|                            |                  | Abcam Inc., Toronto, Ontario, Canada | >1 |
| Ferdinandus et al., 2020    | IHC              | NR               | NR             |
|                            |                  | 28-8             | NR             |
|                            |                  | Abcam Inc., Toronto, Ontario, Canada | NR |
| Forest et al., 2018         | IHC              | NR               | NR             |
|                            |                  | 22C3             | 1:40           |
|                            |                  | Agilent, Santa Clara, CA | >1 |
| Inaguma et al., 2020        | IHC              | Mouse            | NR             |
|                            |                  | EPR4877          | 1:200          |
|                            |                  | Abcam Inc., Toronto, Ontario, Canada | NR |
| Inaguma et al., 2018        | IHC              | Rabbit           | MAB            |
|                            |                  | E13LN            | 1:200          |
|                            |                  | Cell Signaling Technology, Danvers, MA | >5 |
| Jiang et al., 2020          | IHC              | NR               | NR             |
|                            |                  | NR               | NR             |
|                            |                  | Cell Signaling Technology, Danvers, MA | >5 |
| Kao et al., 2017            | IHC              | Rabbit           | MAB            |
|                            |                  | E13LN            | 1:75           |
|                            |                  | Cell Signaling Technology, Danvers, MA | >5 |
| Mansfield et al., 2014      | IHC              | Mouse            | MAB            |
|                            |                  | 5H1-A3           | 1:300          |
|                            |                  | NR               | NR             |
| Metaxas et al., 2018        | IHC              | Rabbit           | MAB            |
|                            |                  | E13LN            | 1:100          |
|                            |                  | Cell Signaling Technology, Danvers, MA | >1 |
| Muller et al., 2020         | IHC              | Rabbit           | MAB            |
|                            |                  | E13LN            | 1:100          |
|                            |                  | Cell Signaling Technology, Danvers, MA | >1 |
| Nguyen et al., 2018         | IHC              | Rabbit           | MAB            |
|                            |                  | SP263            | NR             |
|                            |                  | Ventana          | NR             |
| Sobhani et al., 2019        | IHC              | NR               | MAB            |
|                            |                  | 22C3             | 1:50           |
|                            |                  | Agilent Dako     | NR             |
| Tallón de Lara et al., 2018 | IHC              | NR               | MAB            |
|                            |                  | E13LN            | 1:1000         |
|                            |                  | Cell Signaling Technology, Danvers, MA | >1 |
| Thapa et al., 2017          | IHC              | Rabbit           | MAB            |
|                            |                  | E13LN            | NR             |
|                            |                  | Cell Signaling Technology, Danvers, MA | >1 |
| Watanabe et al., 2018       | IHC              | NR               | MAB            |
|                            |                  | SP142            | NR             |
|                            |                  | Ventana Medical Systems, Tucson, AZ | >1 |
| Prospective studies         |                  |                  |                |
| Brosseau et al., 2019       | IHC              | NR               | MAB            |
|                            |                  | E13LN            | 1:400          |
|                            |                  | CST or Ozyome    | >1 |
| Cedres et al. 2016          | IHC              | Rabbit           | MAB            |
|                            |                  | E13LN            | 1:1200         |
|                            |                  | Cell Signaling Technology, Danvers, MA | >1 |
| Disselhorst et al., 2019    | IHC              | NR               | MAB            |
|                            |                  | 22C3             | NR             |
|                            |                  | Agilent Dako     | Santa Clara, CA | >1 |
| Quispel-Janssen et al., 2018 | IHC              | NR               | MAB            |
|                            |                  | 28-8             | NR             |
|                            |                  | Agilent Dako     | Santa Clara, CA | >1 |

(continued)
**Characteristics of Included Studies**

A summary of the included studies is presented in Table 1. The studies were published from 2014 to 2020. The sample size of the individual studies ranged from 10 to 329, with this review including 3162 patients overall. The median ages of participants ranged from 49.0 to 77.5 years. Study designs included 24 observational studies (19 retrospective, 29–32 and one cross-sectional 33) and five interventional studies (three nonrandomized 34–36 and two randomized study designs 37,38). Quality of the included studies was measured using ROBINS-I in the 27 observational and not randomized studies, based on which 12, 13, and two studies were assessed as having low, moderate, and high risk of bias, respectively (see Table 1). The quality of the two randomized studies was assessed using the Cochrane RoB2 tool, both of which were assessed as having some concern of bias. 37,38 A total of 23 studies included in this SLR provided data on the association between PD-L1 and OS, six studies reported data on PFS, 12,18,22,29,31,36 four on ORR, 12,22,36,38 and two on DCR. 22,38 Regarding patient populations, eight studies included study populations who were previously treated with first and subsequent lines of chemotherapy. 5,12,18,31,34,36–38 There were 11 studies, some reporting on multiple treatments, which included patients treated with immuno-oncology (IO) drugs (n = 5 nivolumab [3 mg/kg or fixed dose of 240 mg], 12,18,32,36,38 n = 5 pembrolizumab [2-10 mg/kg or fixed dose of 200mg], 15,18,22,34,37 n = 2 ipilimumab [1 mg/kg], 31,36 and n = 1 durvalumab plus tremelimumab [NR]; four studies, some reporting on multiple treatments, which included patients treated with chemotherapies (n = 1 pemetrexed [NR]; 29 n = 1 cisplatin plus pemetrexed [NR], 26 n = 2 gemcitabine [1000 mg/m²], 26,37 n = 1 platinum-based chemotherapy [NR], 29, and n = 1 vinorelbine [30, 60, 80 mg/m²]) 17; one study which included patients treated with chemotherapy in combination with radiation treatment; 14 and one chemotherapy in combination with bevacizumab. 29 The remaining 15 studies did not specify which treatments were received by the included patients; however, given the observational nature of these studies, one can consider the patients in these studies to have received the standard of care available at that time. Given the time frame during which patients were enrolled into these studies (Table 1), the standard of care was unlikely to have comprised IO treatment, and as such, these were categorized as non–IO studies in the remainder of the Results section. A summary of the methods of PD-L1 detection across the included studies can be found in Table 2. PD-L1 was detected using IHC in all included studies; the most frequently used anti–PD-L1 clones were E1L3N, 22C3, 28-8, and SP263.

| Primary Antibody Source | Antibody Type | Antibody Clone | Antibody Dilution | Antibody Company | Detection Method |
|-------------------------|--------------|----------------|-------------------|------------------|-----------------|
| Cross-sectional studies | IHC          | 29E.2A3         | NR                | 1:100            | BioLegend, San Diego, CA |
| Nonrandomized trials    | Mouse        | NR             | NR                | NR               | NR              |
| Okada et al., 2019      | IHC          | 22C3           | NR                | 1:80             | Dako pharmDx, Carpinteria, CA |
| Scherpereel et al., 2019| IHC          | SP263          | NR                | 1:100            | Dako pharmDx, Carpinteria, CA |
| Popat et al., 2020      | IHC          | E1L3N          | 28-8              | NR               | NR              |
| Scherpereel et al., 2019| IHC          | SP263          | NR                | 1:100            | NR              |

**Table 2. Continued**

| Study          | Primary Antibody Source | Antibody Type | Antibody Clone | Antibody Dilution | Antibody Company | Detection Method |
|----------------|-------------------------|--------------|----------------|-------------------|------------------|-----------------|
| Cross-sectional studies | Mouse | NR | NR | NR | NR | NR |
| Nonrandomized trials    | Mouse | NR | NR | NR | NR | NR |
| Okada et al., 2019      | Mouse | NR | NR | NR | NR | NR |
| Scherpereel et al., 2019| Mouse | NR | NR | NR | NR | NR |
| Popat et al., 2020      | Mouse | NR | NR | NR | NR | NR |

*IC, immunohistochemistry; MAB, monoclonal antibody; NR, not reported.*
Prognostic Nature of PD-L1 on Clinical Outcomes in MPM

Overall, there were 23 studies providing data on the relationship between PD-L1 expression and OS. Of these, 18 studies reported median OS stratified for individuals classified as having PD-L1–negative (range: 6.1–24.0 mo) and individuals classed as having PD-L1–positive tumors (range: 2.0–27.0 mo). Of the 22 studies that provided a statistical assessment of the comparability of survival distributions, 11 studies did not report significant differences (ranging between 𝑝 = 0.89 to 𝑝 = 0.08),12,13,18,22,24,25,29,31,36,37 10 studies reported results consistent with a statistically significant (ranging between 𝑝 = 0.04 to 𝑝 < 0.0001) higher risk of death in patients with PD-L1–positive tumors compared with PD-L1–negative tumors (hazard ratio [HR] ranging 1.10–3.91),5,17,19,20,21,23,26,27,30 and one study (include patient treated with IO therapy) reported results consistent with a statistically significant (𝑝 = 0.007) lower risk of death in PD-L1–positive compared with PD-L1–negative individuals (HR = 0.16 [95% CI: 0.04–0.73]).31

Overall, six studies reported median PFS stratified by individuals classified as having PD-L1–negative tumors

Figure 2. Forest plot displaying crude (blue) and adjusted (red) HRs comparing the hazard of death in individuals classified according to PD-L1 expression. Where HRs are not reported but a 𝑝 value from a relevant statistical test (e.g., log-rank test), these are provided to provide indication of statistical significance of differences in survival distributions. *HRs describe increase in hazard for every 10% increase in PD-L1 expression. CI, confidence interval; HR, hazard ratio; NR, not reported; OS, overall survival; PD-L1, programmed death-ligand 1; Ref., reference.

Figure 3. Forest plot displaying crude (blue) and adjusted (red) HRs comparing the hazard of death in individuals treated with anti-PD-1 therapy classified according to PD-L1 expression. Where HRs are NR but a 𝑝 value from a relevant statistical test (e.g., log-rank test), these are provided to provide indication of statistical significance of differences in survival distributions. CI, confidence interval; HR, hazard ratio; NR, not reported; OS, overall survival; PD-1, programmed cell death protein-1; PD-L1, programmed death-ligand 1; Ref., reference.
(range: 1.7–9.5 mo) and individuals classed as having PD-L1–positive tumors (range: 2.5–16.4 mo)\textsuperscript{12,18,22,29,31,36,37}. Among the five studies that provided a statistical assessment of the difference in PFS, three studies (all including IO-treated patients) reported statistically significant (ranging between \( p = 0.04 \) and \( p = 0.0018 \)) longer PFS in individuals classed as having PD-L1–negative tumors compared with individuals classed as having PD-L1–positive tumors, whereas three studies (two containing IO-treated patients and one containing non-IO-treated patients) did not identify a statistically significant difference (ranging between \( p = 0.11 \) and \( p = 0.84 \)) between these groups.

**Clinical Outcomes by PD-L1 Expression in Non-IO-Treated Patients**

There were 17 studies providing data on the relationship between PD-L1 expression and OS in patients treated with non-IO therapies. Of these, 14 studies reported median OS stratified for individuals classified as having PD-L1–positive (range: 2.0–27.0 mo) and PD-L1–negative tumors (range: 8.0–24.0 mo) (see Fig. 2). Of the 16 studies that provided a statistical assessment of the comparability of survival distributions, six studies did not report significant differences (ranging between \( p = 0.87 \) to \( p = 0.08 \))\textsuperscript{13,24,25,28,29} and 10 studies reported results consistent with a statistically significant (ranging between \( p = 0.04 \) to \( p < 0.0001 \)) higher risk of death in patients with PD-L1–positive tumors compared with those with PD-L1–negative tumors (HR ranging 1.10–3.91)\textsuperscript{5,17,19,20,21,23,26,27,30}. Studies that reported multivariable models that adjusted for age, sex, disease subtype (e.g. epithelioid, sarcomatoid, and biphasic subtypes) and other factors consistently identified an association between PD-L1 expression and poor OS. Two studies did not report significant differences (\( p = 0.2 \) and \( p = 0.55 \))\textsuperscript{14,29} whereas six of the studies reported results consistent with a statistically significant (ranging between \( p = 0.04 \) to \( p = 0.001 \)) higher risk of death in individuals with PD-L1–positive tumors compared with those with PD-L1–negative tumors (HR ranging 1.1–2.2)\textsuperscript{5,8,20,23,24,30}. Notably, among all the studies with no significant findings, the direction of effect (i.e., median survival or HR) was consistent with poorer survival of patients with PD-L1–positive tumors in all but one of the studies. The effect of different PD-L1 expression cutpoints on OS was explored in six studies\textsuperscript{5,19,22,23,27,29}. Three of these studies reported results consistent with a statistically significant increased hazard of death in individuals with greater than or equal to 50% PD-L1 expression compared with those with less than 50% PD-L1 expression (HR = 1.93 [95% CI: 1.27–2.93], \( p = 0.002 \))\textsuperscript{29} or less than 5% PD-L1 expression (\( p \leq 0.01 \))\textsuperscript{27}.

Two non-IO studies were identified providing data on the association between PD-L1 and PFS in MPM. Brosseau et al.\textsuperscript{29} reported on 448 patients from the BioMAPS prospective cohort treated with pemetrexed plus cisplatin and bevacizumab (\( n = 223 \)) or pemetrexed plus cisplatin (\( n = 223 \)) from February 2008 to January 2014. This study reported shorter median PFS in individuals with PD-L1 expression greater than 1% (6.9 mo) compared with individuals with PD-L1 expression less than or equal to 1% (9.5 mo). The aHR (adjusted for disease subtype (epithelioid, sarcomatoid, or biphasic), performance status, smoking, and treatment arm) was consistent with no significant difference (\( p = 0.84 \)) in PFS between PD-L1 expression groups (aHR = 0.97 [95% CI: 0.72–1.31]). When a higher PD-L1 cutpoint (50%) was used, a shorter median PFS was reported in individuals with PD-L1 expression greater than 50% (6.2 mo) compared with individuals with PD-L1 expression less than or equal to 50% (9.2 mo). Unadjusted HR supported a significantly lower PFS in the greater than 50% PD-L1 expression groups compared with the less than or equal to 50% PD-L1 group (\( p = 0.001 \)); however, this became not significant when adjusted for disease subtype, performance status, smoking, and treatment arm (\( p = 0.37 \)). The second study reporting PFS data in
non–IO-treated patients provided median PFS in chemotherapy-treated patients based on PD-L1 thresholds of 1% and 20% but did not report a statistical assessment of the difference in PFS between these groups.\(^{37}\)

**Clinical Outcomes by PD-L1 Expression in IO-Treated Patients**

Six studies reported on the association between PD-L1 expression and OS in patients receiving IO therapies (Fig. 3).\(^{12,18,22,31,36,37}\) One study\(^ {31}\) reported results consistent with a statistically significant (\(p = 0.007\)) lower risk of death in individuals classified with PD-L1–positive compared with PD-L1–negative expressing tumors (HR = 0.16 [95% CI: 0.04–0.73]). Among the other five studies, statistically significant differences in survival were not reported (ranging between \(p = 0.1\) and \(p = 0.87\)); however, it is notable that median survival and HR estimates (HR range: 0.54–0.84) consistently suggested a direction of effect consistent with IO-treated patients with PD-L1–positive tumors having longer survival than IO-treated patients with PD-L1–negative tumors.

The same six studies also reported data comparing PFS between PD-L1–positive and PD-L1–negative tumor groups treated with anti–programmed cell death protein-1 (PD-1) therapy (Fig. 4).\(^ {12,18,22,31,36,37}\) Again, all results were directionally consistent with longer PFS in PD-L1–positive tumor groups. Among the five studies that provided a statistical assessment of the difference in PFS, two of the studies reported statistically significant (\(p = 0.0018\) and \(p = 0.029\)) longer PFS in patients with tumors expressing PD-L1 greater than or equal to 1% compared with patients with tumors expressing PD-L1 less than 1%.\(^ {18,31}\) whereas two studies did not identify a statistically significant difference (\(p = 0.11\) and \(p = 0.449\)) between these groups.\(^ {12,36}\) The final study reported statistically significant (\(p = 0.04\)) longer PFS in those with PD-L1 greater than or equal to 50% compared with those with PD-L1 less than 5% (HR = 0.36 [95% CI: 0.14–0.93]); however, this association was no longer observed when an adjusted model was used (HR = 0.46 [95% CI: 0.17–1.26]) to account for baseline differences between groups.\(^ {22}\)

**Clinical Outcomes by PD-L1 Expression and IO Treatment Versus Chemotherapy**

One study was identified directly comparing clinical outcomes by IO treatment status in patients with tumors expressing different levels of PD-L1, the randomized controlled PROMISE-Meso trial.\(^ {37}\) This open-label, 1:1, randomized, phase 3 trial investigated the efficacy of pembrolizumab versus chemotherapy (gemcitabine or vinorelbine) in 144 patients with progressive MPM (after platinum-based chemotherapy). Descriptive results of these studies have been reported in the previous sections; here, we report the results of the formal comparisons made within subgroups. This study reported no difference in OS and PFS between treatment arms in subgroups of patients with PD-L1 less than 1% (OS: HR = 0.96, 95% CI: 0.53–1.75; PFS: HR = 0.76, 95% CI: 0.44–1.30), greater than or equal to 1% (OS: HR = 1.09, 95% CI: 0.57–2.09; PFS: HR = 0.76, 95% CI: 0.44–1.30), less than 20% (OS: HR = 0.96, 95% CI: 0.59–1.55; PFS: HR = 0.95 95% CI: 0.62–1.45), and greater than or equal to 20% (OS: HR = 1.11, 95% CI: 0.36–3.40; PFS: HR = 0.95, 95% CI: 0.62–1.45).

**Discussion**

The identification of biomarkers predicting response to immunotherapy with PD-1– and PD-L1–targeted monoclonal antibodies is an area of active investigation and debate across several areas of oncology. This has led to the use of PD-L1 to define treatment-eligible subgroups in several tumor types, including NSCLC, bladder cancer, cervical cancer, and breast cancer. Within MPM, the scientific conversation has been characterized by the reporting of conflicting findings in the literature regarding the relationship between PD-L1 expression, PD-1 or PD-L1–targeted immunotherapy, and clinical outcomes. This SLR seeks to support debate on this topic by providing a comprehensive and updated overview of work in this area.

This SLR identified 29 studies published during 2014 to 2020, reporting on PD-L1 expression and clinical outcomes in patients with MPM. There were 23 that reported data on the association between PD-L1 and OS, whereas six studies provided data on PFS. Among patients receiving non–IO therapy, individuals classified as having PD-L1–positive tumors seemed to have poorer prognosis compared with individuals classified with having PD-L1–negative tumors. In contrast, among patients receiving IO therapy, similar (four studies) or better (one study) survival was observed in individuals classified with having PD-L1–positive tumors compared with individuals classified with having PD-L1–negative tumors. These results are further discussed subsequently.

Across the 14 studies reporting data on OS in which the populations were not specified to have received treatment with PD-1 or PD-L1–targeted therapies, those individuals with tumors expressing PD-L1 seem to have poorer prognosis than those expressing no PD-L1. In contrast, in the six studies that formally compared outcomes by PD-L1 status among individuals known to have been treated with PD-1 or PD-L1–targeted therapies, similar (\(n = 5\)) or better (\(n = 1\)) survival in patients with
tumors expressing PD-L1 compared with patients without PD-L1–expressing tumors was observed. Taken together, these findings suggest that the baseline progression of patients with PD-L1–positive tumors may be poorer than that of patients with PD-L1–negative tumors and that the outcomes observed in the populations treated with PD-1 or PD-L1–targeted therapies may reflect an improvement in the survival of the PD-L1–positive patients to a level similar to or, in some cases, better than that of PD-L1–negative patients.

Although this observation provides some evidence to suggest a prognostic and therapy-dependent predictive role for PD-L1 in MPM, cross-study comparisons may be biased by a variety of factors, and one would ideally draw such conclusions from studies comparing outcomes among patients with similar PD-L1 status who were and were not treated with PD-1 or PD-L1–targeted therapies. Only one study of this nature was identified in this review, in which outcomes in PD-L1–positive and PD-L1–negative patients treated with pembrolizumab were not found to significantly differ from those in chemotherapy-treated patients. The CheckMate-743 trial, which was published because this review was carried out, provides further data regarding the predictive role of PD-L1 in MPM. This phase 3, randomized trial of 605 patients with unresectable MPM was the only study after Popat et al. to prospectively study the role of PD-L1 in MPM. An unpowered exploratory subgroup analysis of the trial focusing on PD-L1 revealed a potentially different OS benefit of nivolumab plus ipilimumab versus chemotherapy in patients with PD-L1 expression greater than or equal to 1% (median OS = 18.0 versus 13.3 mo, HR = 0.69 [95% CI: 0.55–0.87]) versus those with expression less than 1% (median OS = 17.3 versus 16.5 mo, HR = 0.94 [95% CI: 0.62–1.40]). In the patients randomized to chemotherapy treatment in this trial, consistent with the cross-study observations in this review, survival among patients with tumors expressing PD-L1 greater than or equal to 1% (median = 13.3, 95% CI: 11.6–15.4) seems poorer than that in patients with tumors with PD-L1 less than 1% (median = 16.5, 95% CI: 13.4–20.5). In contrast, survival among patients treated with nivolumab plus ipilimumab with tumors expressing PD-L1 greater than or equal to 1% (median = 18.0) seems similar to that in patients with tumors expressing PD-L1 less than 1% (median = 17.3). Notably, across the studies in this review in which anti–PD-1 therapy was used, the only significant finding of this nature observed was also in a population treated with second or subsequent line of nivolumab plus ipilimumab in patients experiencing disease progression or recurrence after platinum-containing systemic therapy. Again, the CheckMate-743 findings should be interpreted with caution because this was an unpowered exploratory analysis of unstratified PD-L1 subgroups and requires further study.

The results reported here must be taken in context of the small sizes of the studies included in the review, their observational nature, and the quality of information reported. That is, although the body of data provides some evidence suggestive of a potential prognostic and predictive role of PD-L1 in MPM, it is possible that this results from heterogeneity in population characteristics (such as previous therapies received, lines of therapy received, disease subtype (epithelioid, sarcomatoid, or biphasic), stage, and performance status) and approaches to PD-L1 measurement (such as variations in PD-L1 assays and clones used, PD-L1 positivity cutpoint, cell type assessed [e.g., tumor cells versus immune cells], and time point assessed). No consistent trends in outcomes across these factors were observed. Findings are also contingent on the assumption that the 15 studies in which the treatments received were not specified did not include patients exposed to PD-1 or PD-L1–targeted therapies. This assumption seems plausible based on the nature and time period of the studies, and any exposure to such treatments in these studies that did occur would be expected to be minimal and therefore have a relatively small impact on our conclusions. Variation was also observed in the quality of the included studies, with 12, 13, and 2 studies assessed as having low, moderate, or high risk of bias, respectively.

In addition, variation in PD-L1 cutpoint may be a source of heterogeneity between studies. Studies that have assessed the association between PD-L1 and OS based on higher expression cutoffs reported slightly more consistent results, with 3 of 4 studies investigating the relationship between PD-L1 greater than or equal to 50% and OS identifying a significantly poorer survival in these patients compared with individuals with PD-L1 less than 5%, whereas smaller not significant differences were observed when comparing those with PD-L1 in the 5% to 49% range to those with PD-L1 less than 5%. Although one of these findings was no longer significant after adjustment for patient characteristics, these results do suggest that more consistency may be obtained at higher PD-L1 thresholds and that the heterogeneity observed in other studies may be related to the distribution of PD-L1 expression levels observed across the populations. If this is the case, future studies might be better to focus on modeling PD-L1 expression as a continuous rather than a categorical variable. Notably, in the one study that took a more continuous approach to modeling PD-L1 expression, a significant association ($p = 0.002$) between 10% increments in PD-L1 expression and OS was observed.
A recent 2020 meta-analysis of the prognostic value of PD-L1 in MPM was conducted, including 16 studies reporting data on the relationship between PD-L1 and OS. This SLR provided updated information, including an additional seven studies regarding the relationship between PD-L1 and OS. Nevertheless, given the limitations of the evidence base, a meta-analysis was not carried out as part of this review and caution must be used when interpreting the results of the 2020 meta-analysis, including many of the studies captured in this review. Although the study reported a pooled HR suggestive of an association between high PD-L1 expression and poorer OS (HR = 1.53 [95% CI: 1.28–1.83]), the finding may be heavily affected by some or all of the heterogeneity described previously.

In conclusion, biomarkers capable of identifying patient groups who will gain most benefit from specific treatments, and therefore guide treatment choice, have the potential to offer significant benefits to both patients and health systems. Nevertheless, it is important that they are only used when the evidence base is strong enough to ensure that their potential benefits do not come at the cost of harming patients. In this regard, although this review has identified evidence to suggest that further investigation of the role of PD-L1 in MPM may be warranted, the current evidence base is not sufficient to influence clinical decision-making at this time. As such, it is suggested that further, high-quality studies focused specifically on the role of PD-L1 in MPM, especially randomized controlled trials comparing clinical outcomes in patients with varying PD-L1 tumor expressions across different treatment arms, are required before any firm conclusions can be drawn regarding its potential role in clinical practice.

CRediT Authorship Contribution Statement

Bristol-Myers Squibb contributed to the design and reporting of the analysis.

Aaron Mansfield: Conceptualization, Writing - original draft, Writing - review & editing.

Rebecca J. Brown, Cormac Sammon: Methodology, Investigation, Formal analysis, Data curation, Writing - original draft, Writing - review & editing, Visualization.

Melinda J. Daumont: Conceptualization, Methodology, Resources, Writing - review & editing, Supervision, Project administration, Funding acquisition.

Mike McKenna: Conceptualization, Methodology, Resources, Writing - review & editing, Supervision, Project administration.

Jenine K. Sanzari: Writing - review & editing, Project administration.

Patrick M. Forde: Conceptualization, Writing - review & editing.

Acknowledgments

This work was supported by Bristol-Myers Squibb. Bristol-Myers Squibb contributed to the study design and reporting of the analysis.

Supplementary Data

Note: To access the supplementary material accompanying this article, visit the online version of the JTO Clinical and Research Reports at www.jtocrr.org/ and at https://doi.org/10.1016/j.jtocrr.2022.100315.

References

1. Baas P, Fennell D, Kerr KM, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v31–v39.
2. Cavone D, Caputi A, De Maria L, et al. Epidemiology of mesothelioma. Environments. 2019;6:76.
3. Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC. Temporal and spatial heterogeneity of programmed cell death 1-ligand 1 expression in malignant mesothelioma. OncolImmunology. 2017;6:e1356146.
4. Van Gerwen M, Alpert N, Wolf A, et al. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database. Carcinogenesis. 2019;40:529–536.
5. Cedrés S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015;10:e0121071.
6. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375–386.
7. Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and safety of nivolumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5:351–357.
8. Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol. 2016;52:9–18.
9. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
10. Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;1–8.
11. Higgins J, Sterne JA, Savovic J, et al. A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev. 2016;10(suppl 1):29–31.
12. Cantini L, Belderbos RA, Gooijer CJ, et al. Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. Transl Lung Cancer Res. 2020;9:1169–1179.
13. Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. *Hum Pathol.* 2019;87:11-17.

14. de Perrot M, Wu L, Cabanero M, et al. Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma. *J Thorac Cardiovasc Surg.* 2020;159:2082-2091.e1.

15. Ferdinandus J, Barbato F, Chodyla M, et al. Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. *J Nucl Med.* 2021;62:191-194.

16. Forest F, Patoir A, Dal Col P, et al. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications. *Pathology.* 2018;50:635-641.

17. Inaguma S, Lasota J, Wang Z, et al. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. *Hum Pathol.* 2018;71:1-7.

18. Jiang Q, Ghafoor A, Mian I, et al. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. *Sci Transl Med.* 2020;12:eaaaz7252.

19. Inaguma S, Lasota J, Czapiewski P, et al. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. *J Pathol.* 2020;250:205-216.

20. Kao SC, Cheng YY, Williams M, et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. *J Thorac Oncol.* 2017;12:1421-1433.

21. Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. *J Thorac Oncol.* 2014;9:1036-1040.

22. Metaxas Y, Rivalland G, Mauti LA, et al. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. *J Thorac Oncol.* 2018;13:1784-1791.

23. Muller S, Victoria Lai W, Adusumilli PS, et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. *Mod Pathol.* 2020;33:303-311.

24. Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S, PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. *Asia Pac J Clin Oncol.* 2018;14:69-73.

25. Sobhani N, Roviello G, Pivetta T, et al. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. *Mol Biol Rep.* 2019;46:2713-2720.

26. Tallón de Lara P, Cecconi V, Hiltbrunner S, et al. Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients. *Clin Cancer Res.* 2018;24:6345-6354.

27. Thapa B, Salcedo A, Lin X, et al. The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma. *J Thorac Oncol.* 2017;12:850-859.

28. Watanabe T, Okuda K, Murase T, et al. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. *Oncotarget.* 2018;9:20769-20780.

29. Brosseau S, Daniel M, Scherpereel A, et al. Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the bio-MAPS cohort. *Clin Lung Cancer.* 2019;20:e564-e575.

30. Cedres SP-A, Pardo-Aranda S, Navarro-Mendivil N, et al. Analysis of expression of PTEN/P53K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPS). *Lung Cancer.* 2016;96:1-6.

31. Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. *Lancet Respir Med.* 2019;7:260-270.

32. Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. *J Thorac Oncol.* 2018;13:1569-1576.

33. Salaroglio IC, Kopecka J, Napoli F, et al. Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma. *J Thorac Oncol.* 2019;14:1458-1471.

34. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 2b trial. *Lancet Oncol.* 2017;18:623-630.

35. Chiariucci C, Cannito S, Daffina MG, et al. Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: correlation with survival. *Cancers (Basel).* 2020;12:361.

36. Okada M, Kijima T, Aoe K, et al. Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma. *J Thorac Oncol.* 2019;25:5485-5492.

37. Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. *Ann Oncol.* 2020;31:1734-1745.

38. Scherpereel A, Mazieres J, Grellier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. *Lancet Oncol.* 2019;20:239-253.

39. Jin L, Gu W, Li X, Xie L, Wang L, Chen Z. PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study. *Ther Adv Med Oncol.* 2020;12:1758835920962362.